Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) have been given an average recommendation of “Buy” by the thirty-two research firms that are covering the firm, Market Beat reports. Two analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation, seventeen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $156.03.

A number of analysts recently commented on the company. RBC Capital reaffirmed an “outperform” rating on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday. Guggenheim reissued a “buy” rating and issued a $195.00 target price on shares of Valeant Pharmaceuticals Intl in a research report on Thursday, January 14th. Mizuho decreased their target price on Valeant Pharmaceuticals Intl from $130.00 to $112.00 and set a “neutral” rating for the company in a research report on Thursday, January 7th. BMO Capital Markets reissued a “market perform” rating and issued a $133.00 target price on shares of Valeant Pharmaceuticals Intl in a research report on Thursday, January 7th. Finally, Susquehanna started coverage on Valeant Pharmaceuticals Intl in a research report on Wednesday, January 6th. They issued a “neutral” rating and a $105.00 target price for the company.

Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 98.57 on Friday. Valeant Pharmaceuticals Intl has a 12-month low of $69.33 and a 12-month high of $263.81. The firm has a market cap of $33.82 billion and a PE ratio of 56.62. The stock’s 50 day moving average price is $98.64 and its 200-day moving average price is $160.68.

A number of hedge funds and institutional investors have made changes to their positions in the stock. Raymond James Trust increased its position in shares of Valeant Pharmaceuticals Intl by 1.0% in the fourth quarter. Raymond James Trust now owns 2,515 shares of the specialty pharmaceutical company’s stock worth $256,000 after buying an additional 24 shares in the last quarter. Acadian Asset Management increased its position in shares of Valeant Pharmaceuticals Intl by 31.8% in the fourth quarter. Acadian Asset Management now owns 2,900 shares of the specialty pharmaceutical company’s stock worth $293,000 after buying an additional 700 shares in the last quarter. Capstone Asset Management Company increased its position in shares of Valeant Pharmaceuticals Intl by 2.0% in the fourth quarter. Capstone Asset Management Company now owns 41,397 shares of the specialty pharmaceutical company’s stock worth $4,208,000 after buying an additional 813 shares in the last quarter. Jennison Associates increased its position in shares of Valeant Pharmaceuticals Intl by 0.8% in the third quarter. Jennison Associates now owns 308,200 shares of the specialty pharmaceutical company’s stock worth $54,977,000 after buying an additional 2,364 shares in the last quarter. Finally, Simplex Trading increased its position in shares of Valeant Pharmaceuticals Intl by 242.9% in the fourth quarter. Simplex Trading now owns 3,412 shares of the specialty pharmaceutical company’s stock worth $1,850,000 after buying an additional 2,417 shares in the last quarter.

Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (NYSE:VRX) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

12 Month Chart for NYSE:VRX

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.